{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:44:59Z","timestamp":1775245499844,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12185-022-03378-w","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T03:47:50Z","timestamp":1652759270000},"page":"553-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis"],"prefix":"10.1007","volume":"116","author":[{"given":"Kihyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawara","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Laure","family":"Risse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"6","key":"3378_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"issue":"8","key":"3378_CR2","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3378_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000117572","volume":"119","author":"SH Kang","year":"2008","unstructured":"Kang SH, Kim TY, Kim HY, Yoon JH, Cho HI, Yoon SS, et al. Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol. 2008;119(1):60\u20134.","journal-title":"Acta Haematol"},{"key":"3378_CR4","volume-title":"Cancer in Thailand","author":"T Khuhaprema","year":"2013","unstructured":"Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang S. Cancer in Thailand, vol. 7. Thailand: Bangkok Ministry of Public Health and Ministry of Education; 2013."},{"key":"3378_CR5","doi-asserted-by":"crossref","unstructured":"Lee JH, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. Int J Hematol. 2010; 92(1):52\u20137.","DOI":"10.1007\/s12185-010-0617-6"},{"key":"3378_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canep.2018.06.003","volume":"55","author":"CH Tang","year":"2018","unstructured":"Tang CH, Liu HY, Hou HA, Qiu H, Huang KC, Siggins S, et al. Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiol. 2018;55:136\u201341.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"3378_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4143\/crt.2013.262","volume":"47","author":"YG Lee","year":"2015","unstructured":"Lee YG, Bang SM, Lee JO, Kim JW, Lee KW, Kim JH, et al. Five-year follow-up study of monoclonal gammopathy of undetermined significance in a Korean Elderly Urban Cohort. Cancer Res Treat. 2015;47(2):215\u201320.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"3378_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ajh.22095","volume":"86","author":"HK Park","year":"2011","unstructured":"Park HK, Lee KR, Kim YJ, Cho HI, Eun Kim J, Woong Kim K, et al. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. Am J Hematol. 2011;86(9):752\u20135.","journal-title":"Am J Hematol"},{"issue":"2","key":"3378_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12185-011-0995-4","volume":"95","author":"P Watanaboonyongcharoen","year":"2012","unstructured":"Watanaboonyongcharoen P, Nakorn TN, Rojnuckarin P, Lawasut P, Intragumtornchai T. Prevalence of monoclonal gammopathy of undetermined significance in Thailand. Int J Hematol. 2012;95(2):176\u201381.","journal-title":"Int J Hematol"},{"issue":"12","key":"3378_CR10","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1182\/blood-2012-11-466011","volume":"121","author":"SP Wu","year":"2013","unstructured":"Wu SP, Minter A, Costello R, Zingone A, Lee CK, Au WY, et al. MGUS prevalence in an ethnically Chinese population in Hong Kong. Blood. 2013;121(12):2363\u20134.","journal-title":"Blood"},{"key":"3378_CR11","unstructured":"European Medicines Agency. Medicines. Sarclisa. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/sarclisa-0"},{"issue":"10214","key":"3378_CR12","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107.","journal-title":"Lancet"},{"key":"3378_CR13","unstructured":"Sanofi. Sarclisa (isatuximab-irfc) [package insert]. Bridgewater, NJ, Sanofi-Aventis U.S. LCC. 2021. Available from: https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf"},{"key":"3378_CR14","unstructured":"Japan. S. Sarclisa package insert. 2021. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_4291454A1021_1_02"},{"issue":"10292","key":"3378_CR15","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"issue":"2","key":"3378_CR16","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.2217\/fon-2019-0431","volume":"16","author":"P Moreau","year":"2020","unstructured":"Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, et al. Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020;16(2):4347\u201358.","journal-title":"Future Oncol"},{"issue":"4","key":"3378_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-018-0071-x","volume":"8","author":"K Suzuki","year":"2018","unstructured":"Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, et al. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018;8(4):41.","journal-title":"Blood Cancer J"},{"key":"3378_CR18","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, et al. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol. 2019; 110(4):466\u201373.","DOI":"10.1007\/s12185-019-02704-z"},{"issue":"6","key":"3378_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s12185-021-03204-9","volume":"114","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Min CK, Kim K, Lee JJ, Shibayama H, Ko PS, et al. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. Int J Hematol. 2021;114(6):653\u201363.","journal-title":"Int J Hematol"},{"issue":"7","key":"3378_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia\u2014an Asian Myeloma Network study. Am J Hematol. 2014;89(7):751\u20136.","journal-title":"Am J Hematol"},{"issue":"2","key":"3378_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cancergencyto.2006.02.015","volume":"168","author":"SM Bang","year":"2006","unstructured":"Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CJ, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124\u201332.","journal-title":"Cancer Genet Cytogenet"},{"issue":"9","key":"3378_CR22","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/annonc\/mdi273","volume":"16","author":"SY Huang","year":"2005","unstructured":"Huang SY, Yao M, Tang JL, Tsay W, Lee FY, Liu MC, et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol. 2005;16(9):1530\u20138.","journal-title":"Ann Oncol"},{"issue":"15","key":"3378_CR23","first-page":"2663","volume":"125","author":"YY Lai","year":"2012","unstructured":"Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, et al. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Chin Med J (Engl). 2012;125(15):2663\u201370.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"3378_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3816\/CLML.2010.n.031","volume":"10","author":"L Zhang","year":"2010","unstructured":"Zhang L, Qi JY, Qi PJ, Wang YF, Zou DH, Yao HJ, et al. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China. Clin Lymphoma Myeloma Leuk. 2010;10(3):197\u2013204.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3378_CR25","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","volume":"24","author":"X Li","year":"2019","unstructured":"Li X, Chen W, Wu Y, Li J, Chen L, Fang B, et al. 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncologist. 2019;24(11):e1132\u201340.","journal-title":"Oncologist"},{"key":"3378_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5: e349.","journal-title":"Blood Cancer J"},{"issue":"11","key":"3378_CR27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with >\/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355\u201361.","journal-title":"Oncologist"},{"key":"3378_CR28","doi-asserted-by":"crossref","unstructured":"Ikeda T, Sunami K, Huang S-Y, Wang M-C, Koh YI, Min CG, et al. Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed\/refractory multiple myeloma: a subgroup analysis of ICARIA-MM study. Ann Oncol. 2019; 30:ix92 (abstract 2690).","DOI":"10.1093\/annonc\/mdz427.003"},{"issue":"1","key":"3378_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3378_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364.","journal-title":"Lancet Oncol"},{"issue":"10245","key":"3378_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03378-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:46:00Z","timestamp":1664304360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03378-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3378"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03378-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK reports grants from Janssen and BMS, outside the submitted work. KI reports grants from Sanofi, Novartis, AbbVie, Bayer, and SymBio; and personal fees from Takeda, Celgene, ONO, Novartis, Chugai, and Eisai, outside the submitted work. YK reports personal fees and non-financial support from Sanofi during the conduct of the study; and personal fees from Janssen, Bristol Myers Squibb, and ONO, outside the submitted work. PM reports personal fees from Sanofi during the conduct of the study; and personal fees from Celgene, Amgen, and Janssen, outside the submitted work. TM reports research support for his institution from Sanofi and Amgen. YD and M-LR are employees of Sanofi and may hold stock\/shares in the company. KS reports personal fees and other support from Celgene; personal fees from Takeda, ONO, Amgen, Novartis, Sanofi, AbbVie and Janssen; personal fees and non-financial support from BMS during the conduct of the study. C-KM, YK, S-HK, SI, JT, MU, and JSK have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}